Literature DB >> 21291371

In silico methods to assist drug developers in acetylcholinesterase inhibitor design.

J A Bermúdez-Lugo1, M C Rosales-Hernández, O Deeb, J Trujillo-Ferrara, J Correa-Basurto.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by a low acetylcholine (ACh) concentration in the hippocampus and cortex. ACh is a neurotransmitter hydrolyzed by acetylcholinesterase (AChE). Therefore, it is not surprising that AChE inhibitors (AChEIs) have shown better results in the treatment of AD than any other strategy. To improve the effects of AD, many researchers have focused on designing and testing new AChEIs. One of the principal strategies has been the use of computational methods (structural bioinformatics or in silico methods). In this review, we summarize the in silico methods used to enhance the understanding of AChE, particularly at the binding site, to design new AChEIs. Several computational methods have been used, such as docking approaches, molecular dynamics studies, quantum mechanical studies, electronic properties, hindrance effects, partition coefficients (Log P) and molecular electrostatic potentials surfaces, among other physicochemical methods that exhibit quantitative structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291371     DOI: 10.2174/092986711795029681

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  1 in total

1.  The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex.

Authors:  Orly Dym; Wanling Song; Clifford Felder; Esther Roth; Valery Shnyrov; Yacov Ashani; Yechun Xu; Robbie P Joosten; Lev Weiner; Joel L Sussman; Israel Silman
Journal:  Protein Sci       Date:  2016-03-28       Impact factor: 6.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.